Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q92535
UPID:
PIGC_HUMAN
Alternative names:
Phosphatidylinositol-glycan biosynthesis class C protein
Alternative UPACC:
Q92535; O14491
Background:
Phosphatidylinositol N-acetylglucosaminyltransferase subunit C, also known as Phosphatidylinositol-glycan biosynthesis class C protein, plays a crucial role in the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex. This complex is responsible for the transfer of N-acetylglucosamine to phosphatidylinositol, marking the first step in GPI biosynthesis.
Therapeutic significance:
The protein is linked to Glycosylphosphatidylinositol biosynthesis defect 16, a disorder marked by delayed psychomotor development, intellectual disability, and seizures. Understanding the role of Phosphatidylinositol N-acetylglucosaminyltransferase subunit C could open doors to potential therapeutic strategies for this condition.